Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice

Mei Zhou, R. Marc Learned, Stephen J. Rossi, Alex M. DePaoli, Hui Tian, Lei Ling – 16 October 2017 – Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent chronic liver disease for which no approved therapies are available. Despite intensive research, the cellular mechanisms that mediate NAFLD pathogenesis and progression are poorly understood.

Neutrophil gelatinase‐associated lipocalin level is a prognostic factor for survival in rat and human chronic liver diseases

Kyoko Yoshikawa, Motoh Iwasa, Akiko Eguchi, Shinichi Kojima, Naohiko Yoshizawa, Mina Tempaku, Ryosuke Sugimoto, Norihiko Yamamoto, Kazushi Sugimoto, Yoshinao Kobayashi, Hiroshi Hasegawa, Yoshiyuki Takei – 16 October 2017 – Chronic liver disease patients often have complications, such as hepatocellular carcinoma (HCC) and acute bacterial infection. Model for end‐stage liver disease and Child‐Pugh scores are useful prognostic factors for chronic liver diseases but not for all chronic conditions, such as HCC.

CRISPR correction of a homozygous low‐density lipoprotein receptor mutation in familial hypercholesterolemia induced pluripotent stem cells

Linda Omer, Elizabeth A. Hudson, Shirong Zheng, James B. Hoying, Yuan Shan, Nolan L. Boyd – 16 October 2017 – Familial hypercholesterolemia (FH) is a hereditary disease primarily due to mutations in the low‐density lipoprotein receptor (LDLR) that lead to elevated cholesterol and premature development of cardiovascular disease. Homozygous FH patients (HoFH) with two dysfunctional LDLR alleles are not as successfully treated with standard hypercholesterol therapies, and more aggressive therapeutic approaches to control cholesterol levels must be considered.

Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease

Michael S. Middleton, Mark L. Van Natta, Elhamy R. Heba, Adina Alazraki, Andrew T. Trout, Prakash Masand, Elizabeth M. Brunt, David E. Kleiner, Edward Doo, James Tonascia, Joel E. Lavine, Wei Shen, Gavin Hamilton, Jeffrey B. Schwimmer, Claude B.

Erratum: Reassessing the Safety Concerns of Utilizing Blood Donations from Patients with Hemochromatosis

Adam C. Winters, Douglas Tremblay, Suzanne Arinsburg, John Mascarenhas, Thomas D. Schiano – 12 October 2017 – After publication of our manuscript, it came to our attention that the Australian Red Cross does indeed accept blood donations from patient with hemochromatosis (HH).

Myeloid Notch1 deficiency activates the RhoA/ROCK pathway and aggravates hepatocellular damage in mouse ischemic livers

Ling Lu, Shi Yue, Longfeng Jiang, Changyong Li, Qiang Zhu, Michael Ke, Hao Lu, Xuehao Wang, Ronald W. Busuttil, Qi‐Long Ying, Jerzy W. Kupiec‐Weglinski, Bibo Ke – 12 October 2017 – Notch signaling plays an emerging role in the regulation of immune cell development and function during inflammatory response. Activation of the ras homolog gene family member A/Rho‐associated protein kinase (ROCK) pathway promotes leukocyte accumulation in tissue injury.

Subscribe to